Cambridge’s Experimental Cancer Medicine Centre to receive funding for clinical trials
January 18, 2023Medical Communications
The Experimental Cancer Medicine Centre (ECMC) in Cambridge is one of a selection of organisations to receive a share of …
PFIZER EXPANDS ‘AN ACCORD FOR A HEALTHIER WORLD’ PRODUCT OFFERING TO INCLUDE FULL PORTFOLIO FOR GREATER BENEFIT TO 1.2 BILLION PEOPLE IN 45 LOWER-INCOME COUNTRIES
January 18, 2023Business Services
DAVOS, Switzerland, January 17, 2023 – Pfizer Inc.
UCL to begin new trial to assess cough medicine’s impact on Parkinson’s disease
January 17, 2023Medical Communications
Researchers led by a team at University College London (UCL) have began researching the impacts of ambroxol, a common ingredient …
Johnson & Johnson scale back COVID-19 vaccination production
January 17, 2023Manufacturing and Production
US-based Johnson & Johnson (J&J) have begun scaling back production of their COVID-19 vaccine due to demand falling over the …
Thermo Fisher to become founding sponsor of Momentum Labs
January 17, 2023Medical Communications
Thermo Fisher Scientific has announced that it has become a founding sponsor of Momentum Labs in Alachua, Florida, US. The …
Indonesia begins hearing class-action lawsuit after children’s deaths from cough syrup
January 17, 2023Medical Communications
An Indonesian court has begun proceedings to hear a class-action lawsuit against health and finance ministries, the drugs regulator and …
Green Bioactives appoints experienced biotech leaders Chris Meaney and Andy Hall-Ponselé to expand senior management team
January 17, 2023Business Services
Edinburgh, Scotland, 17 January 2023 – Green Bioactives Limited (‘GBL’), a world-leader in the discovery, development and sustainable production of …
AstraZeneca UK, Qure.ai and Greater Manchester Cancer Alliance Join Forces to Battle Lung Cancer Waiting Times Using Artificial Intelligence (AI) Technology
January 17, 2023Business Services
London, UK, 13 January 2023 – An initiative to improve earlier diagnosis of lung cancer has been launched by AstraZeneca UK, …
The Scottish Medicines Consortium recommends Merck’s TEPMETKO® (tepotinib) as the first oral MET inhibitor treatment option for advanced NSCLC adult patients with METex14 skipping alterations
January 16, 2023Business Services
16 January 2023, Feltham (Merck) – Today Merck, a leading science and technology company, announced that following a resubmission to …
Boehringer Ingelheim and 3T Biosciences form $268m partnership to develop next-generation cancer immunotherapies
January 16, 2023Medical Communications
Germany-based Boehringer Ingelheim and US company 3T Biosciences have entered into a strategic collaboration and licensing agreement to research and …
Eli Lilly and AbbVie leave UK VPAS; blow to UK pharma industry
January 16, 2023Medical Communications
Eli Lilly and AbbVie have announced their departure from the voluntary scheme for branded medicines pricing and access (VPAS), causing …
Luye Pharma’s Rykindo® approved by FDA for treatment of schizophrenia and bipolar 1 disorder
January 16, 2023Research and Development
International pharmaceutical company, Luye Pharma, has announced that Rykindo® has received FDA approval for the treatment of schizophrenia in adult …
AstraZeneca’s Tezspire gains CHMP approval for the treatment of severe asthma
January 16, 2023Research and Development
AstraZeneca has announced that Tezspire (also known as tezepelumab) has received approval from the EMA’s Committee for Medicinal Products for …
Poolbeg announces strategic expansion of POLB 001 into oncology
January 16, 2023Business Services
16 January 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical …
finnCap Cavendish advises on the sale of MBI Healthcare Technologies to DNV
January 13, 2023Business Services
London, 9th January – finnCap Cavendish, part of finnCap Group plc, is pleased to announce it has advised the three …
Pfizer’s COVID-19 vaccine under FDA’s examination following new research into adverse side effects
January 13, 2023Medical Communications
The FDA, along with Taiwanese medical institutions, have been evaluating Pfizer’s mRNA COVID-19 vaccine, questioning the CDC’s omission of known …
Diabeloop and EOFlow team up to develop an automated insulin device
January 13, 2023Medical Communications
Diabeloop, a medical device company focused on automated diabetes treatment solutions, and South Korea-based EOFlow have joined forces to offer …
First patient enrolled in Inari DEFIANCE trial for deep vein thrombosis
January 13, 2023Research and Development
Inari Medical has announced that the first patient has been enrolled in the DEFIANCE trial. This trial will evaluate the …
MediciNova completes enrolment for phase 2 clinical trial of ibudilast to treat recurrent and newly diagnosed glioblastoma
January 13, 2023Research and Development
Biopharmaceutical company MediciNova has announced that its phase 2 clinical trial to assess MN-166 (ibudilast) for the treatment of recurring …
Ajinomoto and Exelixis sign agreement to develop novel ADCs for cancer treatment
January 12, 2023Research and Development
Ajinomoto Co., a Japanese biotech company providing biopharmaceuticals, has signed a license agreement with Exelixis Inc., an oncology-focused biotech company, …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
